Analysts Set Health Catalyst, Inc. (NASDAQ:HCAT) Price Target at $11.71

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have been assigned an average rating of “Moderate Buy” from the twelve brokerages that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $11.79.

Several research analysts recently commented on HCAT shares. JPMorgan Chase & Co. lifted their price target on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Stephens lifted their target price on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a report on Thursday, November 14th. Citigroup increased their price target on Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a report on Wednesday, November 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th. Finally, Piper Sandler reissued an “overweight” rating and issued a $12.00 target price (up previously from $11.00) on shares of Health Catalyst in a research note on Tuesday.

Health Catalyst Stock Up 2.1 %

Shares of HCAT opened at $8.83 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The stock has a market capitalization of $537.31 million, a price-to-earnings ratio of -6.54 and a beta of 1.32. Health Catalyst has a 1 year low of $5.42 and a 1 year high of $11.41. The business’s 50 day simple moving average is $8.12 and its 200-day simple moving average is $7.33.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The business had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $76.27 million. During the same period in the previous year, the company earned ($0.22) EPS. Health Catalyst’s revenue for the quarter was up 3.5% compared to the same quarter last year. As a group, equities analysts expect that Health Catalyst will post -0.33 earnings per share for the current fiscal year.

Insider Activity at Health Catalyst

In other news, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $7.68, for a total transaction of $40,005.12. Following the transaction, the chief operating officer now directly owns 134,899 shares of the company’s stock, valued at approximately $1,036,024.32. This trade represents a 3.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the sale, the insider now owns 255,881 shares of the company’s stock, valued at $1,847,460.82. The trade was a 2.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 34,068 shares of company stock worth $257,555 in the last 90 days. 2.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Health Catalyst

Institutional investors have recently made changes to their positions in the company. Primecap Management Co. CA grew its holdings in Health Catalyst by 14.7% during the 2nd quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock worth $15,205,000 after acquiring an additional 305,079 shares in the last quarter. Janney Montgomery Scott LLC purchased a new stake in shares of Health Catalyst in the 3rd quarter worth approximately $897,000. Kennedy Capital Management LLC bought a new position in shares of Health Catalyst during the first quarter valued at approximately $8,780,000. Essex Investment Management Co. LLC purchased a new position in Health Catalyst during the third quarter valued at approximately $2,012,000. Finally, AQR Capital Management LLC bought a new position in Health Catalyst in the second quarter worth approximately $564,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.